Keyword Analysis & Research: biogen idec
Keyword Research: People who searched biogen idec also searched
Search Results related to biogen idec on Search Engine
-
Home | Biogen
https://www.biogen.com:443/
WEBBiogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through …
DA: 13 PA: 56 MOZ Rank: 1
-
Biogen IDEC - Home - Idec Pharma
http://www.idecpharm.com:80/site/home.html
WEBAug 19, 2022 · Biogen Idec invests in its employees. We offer challenges, learning and innovation along with a comprehensive compensation and benefits program. We invite you to join us.
DA: 66 PA: 11 MOZ Rank: 96
-
Biogen - Wikipedia
https://en.wikipedia.org:443/wiki/Biogen
WEBIn 2003, Biogen merged with San Diego, California-based IDEC Pharmaceuticals (formed in 1985 by University of California-San Diego's physicians and immunologists Ivor Royston and Robert E. Sobol, San Diego bio entrepreneur Howard Birndorf, and Stanford University cancer researchers Ron Levy and Richard Miller) and adopted the name Biogen Idec.
DA: 10 PA: 28 MOZ Rank: 92
-
Biogen Idec Becomes Biogen | Biogen
https://investors.biogen.com:443/news-releases/news-release-details/biogen-idec-becomes-biogen
WEBCAMBRIDGE, Mass.--(BUSINESS WIRE)--Effective today, Biogen Idec is known simply as Biogen (NASDAQ: BIIB). The company has introduced a new corporate identity and logo that reflect both its evolution and focus on bringing forth new therapies in areas of high unmet need – while honoring Biogen’s scientific heritage and legacy as a pioneer in ...
DA: 84 PA: 22 MOZ Rank: 41
-
Company | Biogen
https://www.biogen.com:443/company.html
WEBBiogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through …
DA: 2 PA: 63 MOZ Rank: 75
-
Biogen Inc. (BIIB) Stock Price, News, Quote & History - Yahoo Finance
https://finance.yahoo.com:443/quote/BIIB/
WEBBiogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are...
DA: 55 PA: 25 MOZ Rank: 82
-
Biogen and IDEC Pharmaceuticals Announce Merger To Create …
http://www.idecpharm.com:80/news/pr_i006.html
WEBAug 18, 2022 · IDEC has a strong franchise in cancer and a growing focus on autoimmune diseases, while Biogen is strong in the autoimmune area and is increasingly developing capabilities in cancer. The merger is expected to enable the companies to: — achieve cumulative capital expenditure synergies of over $175 million through 2007.
DA: 8 PA: 83 MOZ Rank: 98
-
Samsung and Biogen Idec Announce Joint Venture to Develop, …
https://investors.biogen.com:443/news-releases/news-release-details/samsung-and-biogen-idec-announce-joint-venture-develop
WEBAbout Biogen Idec. Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company.
DA: 68 PA: 67 MOZ Rank: 63
-
Biogen Idec to Expand Neuropathic Pain Portfolio with the …
https://investors.biogen.com:443/news-releases/news-release-details/biogen-idec-expand-neuropathic-pain-portfolio-acquisition
WEBJan 11, 2015 · CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- Biogen Idec (NASDAQ: BIIB) announced today that it has agreed to acquire U.K.-based Convergence Pharmaceuticals, a clinical-stage biopharmaceutical company with an innovative portfolio of ion channel-modulating product candidates for neuropathic pain.
DA: 13 PA: 83 MOZ Rank: 83
-
Biogen Idec and Genentech Announce Restructuring of anti …
https://investors.biogen.com:443/news-releases/news-release-details/biogen-idec-and-genentech-announce-restructuring-anti-cd20
WEBOct 21, 2010 · Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients worldwide benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis.
DA: 21 PA: 34 MOZ Rank: 69